Where is CHALEX's headquarters?
CHALEX's headquarters is located at Po Box 187, Wallowa.
Who are CHALEX's competitors?
Competitors of CHALEX include Inotek Pharmaceuticals, Evogen, BioVidria, GenTel BioSciences, Caliper Life Sciences and 12 more.
You May Also Like
PolyAn Molecular Surface Engineering: fluorescent encoded polymer microspheres (beads), microarray slides and membranes for Pervaporation and organophilic Nanofiltration
Oxford Molecular aims to provide computational chemistry and molecular graphics to European and U.S. markets.
Pepscan provides peptide-based products & services offering knowledge of peptides for drug discovery collaborations. At its end-to-end facility in Lelystad, the Netherlands, Pepscan offers a range of patented technologies, phage display capabilities, a lead-optimization array platform, and production facilities for R&D- to GMP-grade peptides, including libraries and neoantigen vaccines. Among its patents is the CLIPS technology, which locks peptides into active conformations. With its epitope mapping service platform, Pepscan also supports biotech companies in developing their antibody pipelines. The underlying protein mimicry platform delivers binding insights, even in cases where other technologies, such as linear, fall short.
Axela is delivering on its mission to provide a simple and effective approach to personalized medicine by exploiting the dotLab System in research markets today to generate tomorrow's diagnostics. This strategy of offering a common technology platform to both markets aims to provide a opportunity to capitalize on discoveries. The approach has already resulted in applications with the potential to address segments of the large, underserved markets of oncology and cardiology that will be the focus of two funded clinical trials this summer and growing installed customer base. For a time these leading clinical researchers can use the direct understanding of protein interactions to develop quantitative assays on a single platform. dot technology has shortened the transition from protein discovery to application. The ability to measure biomolecular complexes in real-time aims to provide for new approaches to disease management.
FlexGen is working towards the commercialization of a fast and flexible custom microarray synthesis instrument for genomic selection in sequencing and other applications.
Nobody prototypes a jet plane or car without running the empirical data through a computer model. A clinical trial is also a prototype. Now, pharmaceutical companies can simulate as many scenarios as necessary to optimize success in the final design of their clinical trials.nBiosimulation technology from Immunetrics Inc. aims to provide a bridge from research and experiment to trial design. Immunetrics' toolset aims to provide predictive computer models based on biological mechanisms. The inputs are patient data; the outputs are predictions of clinical markers over time and clinically relevant endpoints. Using this data, Immunetrics creates a simulation platform for conducting virtual experiments that can help pharmaceutical companies lock down the design of a human study that is optimized for success.nImmunetrics is the only known mechanistic modeling company to provide predictions of clinical trial outcomes that go far beyond pass or fail.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.